PASG - Passage BIO, Inc.
8.4
0.280 3.333%
Share volume: 66,082
Last Updated: 03-06-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
0.17%
PREVIOUS CLOSE
CHG
CHG%
$8.12
0.28
0.03%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-14-2024 | 08-08-2024 | 11-13-2024 | 03-04-2025 | 05-13-2025 | 11-10-2025 | 03-03-2026 | |
| Total revenue | -26.000 K | 2.000 K | 99.000 K | -24.000 K | -8.000 K | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | -26.000 K | 2.000 K | 99.000 K | -24.000 K | -8.000 K | 0.000 | 0.000 | |
| 107.69% | 4,850.00% | -124.24% | 66.67% | 100.00% | nan% | |||
| Operating expenses | 18.050 M | 16.940 M | 15.907 M | 14.270 M | 13.822 M | 8.655 M | 10.340 M | |
| Selling general and admin | 6.515 M | 6.510 M | 7.251 M | 4.712 M | 6.085 M | 4.348 M | 4.922 M | |
| Research and development | 11.535 M | 10.430 M | 8.656 M | 9.558 M | 7.737 M | 4.307 M | 5.418 M | |
| Total expenses | 18.050 M | 17.378 M | 20.702 M | 14.270 M | 16.459 M | 8.655 M | 13.848 M | |
| -3.72% | 19.13% | -31.07% | 15.34% | -47.41% | 60.00% | |||
| Operating income | -18.050 M | -17.378 M | -20.702 M | -14.270 M | -16.459 M | -8.655 M | -13.848 M | |
| Ebit | -16.711 M | -15.991 M | -19.340 M | -12.725 M | -15.405 M | -7.749 M | -12.983 M | |
| Pretax income | -16.711 M | -15.991 M | -19.340 M | -12.725 M | -15.405 M | -7.749 M | -12.983 M | |
| -4.31% | 20.94% | -34.20% | 21.06% | -49.70% | 67.54% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -16.711 M | -15.991 M | -19.340 M | -12.725 M | -15.405 M | -7.749 M | -12.983 M | |
| 4.31% | -20.94% | 34.20% | -21.06% | 49.70% | -67.54% |